MedPath

Neurofeedback as a Treatment Tool for Depression

Not Applicable
Completed
Conditions
Unipolar Depression
Interventions
Other: fMRI-based neurofeedback
Registration Number
NCT01544205
Lead Sponsor
Cardiff University
Brief Summary

The purpose of the study is to investigate whether neurofeedback delivered via functional magnetic resonance imaging signals can be used to train depressed patients to self-regulate emotion networks and whether this improves clinical symptoms.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
43
Inclusion Criteria
  • major depressive disorder (MDD) diagnosis
  • stable antidepressant dose medication
Exclusion Criteria
  • Other physical or psychiatric disorders
  • Current substance abuse
  • Current psychotherapy or other specific intervention
  • Exclusion criteria applicable to MRI

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Emotion network up-regulationfMRI-based neurofeedbackParticipants use fMRI-based neurofeedback to train the upregulation of brain areas that respond to positive affective pictures (as identified during a functional localiser scan).
Place processing network up-regulationfMRI-based neurofeedbackParticipants use fMRI-based neurofeedback to train the upregulation of brain areas that respond to place and house pictures (as identified during a functional localiser scan).
Primary Outcome Measures
NameTimeMethod
Change from Baseline in Hamilton Depression Rating Scale (HDRS) score at the end of intervention (after 5th session)Before start trial (baseline), after intervention (appr. 2 months)
Secondary Outcome Measures
NameTimeMethod
Change from Baseline in Hospital Anxiety and Depression Scale (HADS) anxiety score at the end of intervention (after 5th session)Baseline, end of intervention (appr. 2 months)
Change from Baseline in Hamilton Depression Rating Scale (HDRS) score at follow-upBaseline, 3-month follow-up
Change from Baseline in Hospital Anxiety and Depression Scale (HADS) anxiety score at follow-upBaseline, 3-month follow-up
Change from Baseline in Hospital Anxiety and Depression Scale (HADS) depression score at the end of intervention (after 5th session)Baseline, end of intervention (appr. 2 months)
Change from Baseline in the Quality of Life Scale (QOLS) at the end of intervention (after 5th session)Baseline, end of intervention (appr. 2 months)
Change from Baseline in Hospital Anxiety and Depression Scale (HADS) depression score at follow-upBaseline, 3-month follow-up
Change from Baseline in the Quality of Life Scale (QOLS) at follow-upBaseline, 3-month follow-up
Change from Baseline in the European Quality of Life-5 dimensions scale (EQ-5D) at follow-upBaseline, 3-month follow-up
Change from Baseline in the European Quality of Life-5 dimensions scale (EQ-5D) at the end of intervention (after 5th session)Baseline, end of intervention (appr. 2 months)

Trial Locations

Locations (2)

CUBRIC

🇬🇧

Cardiff, Wales, United Kingdom

School of Medicine, Cardiff University

🇬🇧

Cardiff, Wales, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath